Heron Therapeutics Inc. Common Stock
HRTXUnited States
5 filed reports · 225 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 672 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 651 | Dec 2025 |
Financial data
225 concepts · 1,323 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial220 concepts · 1,255 facts · Aug 2023 to Jun 2026
- Stockholders equity (US GAAP)14 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value13 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
- Comprehensive income net of tax13 · Dec 2023 to Jun 2026
- Net income loss13 · Dec 2023 to Jun 2026
- Stock issued during period value share based compensation13 · Dec 2023 to Jun 2026
- Allocated share based compensation expense12 · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)12 · Dec 2023 to Jun 2026
- Costs and expenses12 · Dec 2023 to Jun 2026
- Debt securities available for sale realized gain loss12 · Dec 2023 to Jun 2026
- Debt securities, impairment losses12 · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)12 · Dec 2023 to Jun 2026
- Gross profit (US GAAP)12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Other nonoperating income expense12 · Dec 2023 to Jun 2026
- Research and development expense12 · Dec 2023 to Jun 2026
- Revenue12 · Dec 2023 to Jun 2026
- Selling and marketing expense (US GAAP)12 · Dec 2023 to Jun 2026
- Accretion amortization of discounts and premiums investments11 · Dec 2023 to Jun 2026
- Accrued clinical and manufacturing liabilities11 · Dec 2023 to Jun 2026
- Amortization of debt discount premium11 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect11 · Dec 2023 to Jun 2026
- Depreciation depletion and amortization11 · Dec 2023 to Jun 2026
- Increase decrease in accounts payable11 · Dec 2023 to Jun 2026
Product2 concepts · 51 facts · Dec 2023 to Jun 2026
- Revenue48 · Dec 2023 to Jun 2026
- Production related impairments or charges3 · Dec 2023 to Dec 2025
Geography3 concepts · 17 facts · Dec 2023 to Jun 2026
- Operating lease expense7 · Jun 2024 to Jun 2026
- Operating lease payments7 · Jun 2024 to Jun 2026
- Sublease income3 · Dec 2023 to Dec 2025
Segments
68 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service4 members · 51 facts
- ZYNRELEF15 · Dec 2023 to Jun 2026
- Aponvie12 · Dec 2023 to Jun 2026
- CINVANTI12 · Dec 2023 to Jun 2026
- SUSTOL12 · Dec 2023 to Jun 2026
Statement geographical2 members · 17 facts
- CA15 · Dec 2023 to Mar 2026
- NC2 · Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Nov 2025 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 10, 2026
- FY2026 Q1May 11, 2026
- FY2025 Q4Feb 26, 2026
- FY2025 Q3Nov 4, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.